Overview
The long-term goal is to define the mechanisms of pathogenesis underlying Langerhans cell histiocytosis (LCH). The overall objectives of the current study are to characterize the role of SMAD6 inherited genetic variation on LCH susceptibility and identify germline genomic regions associated with LCH somatic mutations. Building from preliminary data, the central hypotheses are: (1) causal genetic variants in SMAD6 underlie susceptibility to LCH, and (2) differences in LCH-related somatic activating mutations by race/ethnicity are related to Amerindian (i.e., Native American) genetic ancestry. The Central hypothesis will be tested by pursuing the specific aims.
Description
PRIMARY OBJECTIVES:
I. To comprehensively characterize germline variants in SMAD6 and their association with LCH.
II. To identify novel germline variants associated with LCH.
III.To determine the role of genetic ancestry on LCH-related somatic mutations.
EXPLORATORY OBJECTIVES:
I. To integrate clinical and epidemiologic questionnaire data with genetic risk factor data from the Primary Aims to more comprehensively elucidate LCH susceptibility.
- OUTLINE
Case identification and recruitment followed by questionnaires and specimen processing.
Eligibility
Inclusion Criteria:
- ≤ 25 years old at the time of original LCH diagnosis
- The patient must be enrolled on ACCRN07 and/or APEC14B1 and registered with COG by a North American member institution
- The patient must have a diagnosis of LCH (ICD Codes/Morphology: 9751/1; 9752/1; 9753/1; or 9754/3).
- The patient must be diagnosed with LCH on or after January 1, 2008.
- All questionnaire respondents must understand English or Spanish.
- All patients and/or their parents or legal guardians must provide informed consent.
- All institutional, FDA, and NCI requirements for human studies must be met.